Jazz Pharmaceuticals PLC (OQ:JAZZ)

May 01, 2024 04:10 pm ET
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
DUBLIN, May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference on Wednesday, May 15, 2024, in Las Vegas. The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.  
May 01, 2024 04:05 pm ET
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
– 12% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 13% year-over-year –– Submitted zanidatamab BLA for 2L BTC; expect to launch in 2025 or earlier –– Top-line Phase 2b data from suvecaltamide trial in essential tremor expected in late 1H24 –– 2024 total revenue guidance affirmed at $4.0 to $4.2 billion –
Apr 30, 2024 09:50 am ET
Jazz Pharmaceuticals Focuses on Taking Actions To Positively Impact the Planet This Earth Month
NORTHAMPTON, MA / ACCESSWIRE / April 30, 2024 / Jazz Pharmaceuticals:
Apr 24, 2024 04:05 pm ET
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
Overall survival and additional long-term follow-up data from the Phase 2b HERIZON-BTC-01 trial in previously treated HER2-positive metastatic biliary tract cancer (BTC) to be presented at ASCO 2024
Apr 23, 2024 11:15 am ET
Apr 17, 2024 04:15 pm ET
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update.  
Apr 10, 2024 07:45 am ET
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
Two oral presentations share results of real-world impact of idiopathic hypersomnia and long-term effectiveness of Epidiolex® (cannabidiol) in treatment-resistant epilepsies
Apr 02, 2024 07:30 am ET
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
Submission based on data from Phase 2b HERIZON-BTC-01 trial, which met its primary endpoint in patients receiving zanidatamab for previously treated HER2-positive biliary tract cancer (BTC)
Mar 28, 2024 10:15 am ET
Cancer and the Combination Approach
Oncology is a tricky sector in which to innovate, but we can start by optimizing existing combination approaches
Mar 20, 2024 10:15 am ET
Jazz Pharmaceuticals Celebrates International Women’s Day
NORTHAMPTON, MA / ACCESSWIRE / March 20, 2024 / Jazz Pharmaceuticals
Mar 14, 2024 12:00 pm ET
Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month
NORTHAMPTON, MA / ACCESSWIRE / March 14, 2024 / Jazz Pharmaceuticals
Feb 27, 2024 06:45 am ET
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
Mr. Kennedy brings wealth of experience managing high growth organizations focused on creating value for shareholders
Feb 21, 2024 06:45 am ET
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
Mr. Johnson Brings Over 35 Years of Financial and Operating Experience to Leadership Team
Feb 20, 2024 03:15 pm ET
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
DUBLIN, Feb. 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:
Feb 14, 2024 03:15 pm ET
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
DUBLIN, Feb. 14, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2023 full year and fourth quarter financial results and provide a business and financial update.
Feb 13, 2024 10:15 am ET
Listen to How "Jazz Remix" Fosters a Positive Employee Experience at Jazz Pharmaceuticals
NORTHAMPTON, MA / ACCESSWIRE / February 13, 2024 / Jazz Pharmaceuticals
Feb 09, 2024 09:15 am ET
How This CEO Built a Top 50 Pharma Company Focusing on Culture Day 1
NORTHAMPTON, MA / ACCESSWIRE / February 9, 2024 / Jazz PharmaceuticalsBy Chase Feiger, M.D.
Feb 07, 2024 01:00 am ET
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales
Dec 21, 2023 03:05 pm ET
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder
DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint. There was not a statistically significant decrease in total PTSD symptom severity as measured by the Clinician Administered PTSD Scale (CAPS-5) between JZP150 (4mg or 0.3mg) compared to placebo from baseline to week 12.
Dec 20, 2023 03:15 pm ET
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
DUBLIN, Dec. 20, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 8, 2024, at 2:15 p.m. PST / 10:15 p.m. GMT.
Dec 08, 2023 12:20 pm ET
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
First presentation of progression-free survival (PFS) primary endpoint data show zanidatamab plus palbociclib and fulvestrant demonstrated a PFS of 67% at 6 months and a median PFS of 12 months in patients with heavily pre-treated HER2+/HR+ metastatic breast cancer (mBC)
Dec 08, 2023 09:15 am ET
Dec 01, 2023 08:02 am ET
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
Data from nine abstracts to be presented, including real-world outcomes of Epidiolex® (cannabidiol) in treatment-resistant focal epilepsies
Nov 30, 2023 06:45 am ET
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
New trial results of investigational bispecific antibody zanidatamab presented at SABCS in HER2+/HR+ metastatic breast cancer
Nov 29, 2023 11:15 am ET
Nov 14, 2023 02:00 am ET
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.
Nov 08, 2023 03:05 pm ET
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
– 3Q23 total revenues of $972 million –– Combined revenues from key growth drivers, Xywav®, Epidiolex® and Rylaze®, increased 24% year-over-year –– Raising total and Oncology revenue guidance at the mid-points –– Plan to initiate zanidatamab rolling biologics license application (BLA) submission this year for accelerated approval in second-line (2L) biliary tract cancers (BTC) –
Nov 07, 2023 06:45 am ET
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers
DUBLIN and HOUSTON, Nov. 7, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
Nov 01, 2023 04:15 pm ET
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
DUBLIN, Nov. 1, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following upcoming investor conferences:
Oct 25, 2023 04:15 pm ET
Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023
DUBLIN, Oct. 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2023 third quarter financial results and provide a business and financial update.  
Oct 23, 2023 07:45 am ET
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Ba
Two presentations focus on cardiovascular disease risk among patients with sleep disorders and the impact of sodium intake on cardiometabolic comorbidities, highlighting the need for low-sodium treatment options
Oct 18, 2023 07:45 am ET
Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023
Meeting presentations underscore the increased need for awareness around the cardiovascular and cardiometabolic comorbidities and modifiable risk factors associated with sleep disorders
Oct 16, 2023 07:45 am ET
Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023
Zanidatamab data demonstrate clinical potential of novel bispecific antibody in HER2-targeted biliary tract and gastric cancers
Oct 06, 2023 10:15 am ET
Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report Puts Patients at the Center
Originally published in Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report
Sep 21, 2023 05:41 pm ET
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymph
DUBLIN, Sept. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted marketing authorization for Enrylaze® (JZP458; a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.[1] Enrylaze, approved as Rylaze® in the United States and Canada
Sep 13, 2023 04:15 pm ET
Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences
DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.
Sep 12, 2023 07:30 am ET
Jazz Pharmaceuticals Announces Key Update to Leadership Team
Renée Galá promoted to President and Chief Operating Officer
Sep 11, 2023 07:45 am ET
Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023
Six presentations demonstrated Jazz's commitment to providing solutions for people living with difficult-to-treat sleep disorders
Aug 02, 2023 02:10 pm ET
Jazz Pharmaceuticals enters into Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Rylaze®, helping address the unmet need of acute lymphoblastic leukemia and lymphoblastic lym
MISSISSAUGA, ON, Aug. 2, 2023 /CNW/ - Jazz Pharmaceuticals Canada Inc. today announced that the Company has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Rylaze® (crisantaspase recombinant) in Canada.1 This allows for individual jurisdictions in Canada to begin formalizing access for eligible patients. Rylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients one year or older who have developed hype
Jul 26, 2023 04:15 pm ET
Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023
DUBLIN, July 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 second quarter financial results on Wednesday, August 9, 2023, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2023 second quarter financial results and provide a business and financial update.  
Jul 21, 2023 08:08 am ET
Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
DUBLIN, July 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorization of JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-deri
Jun 02, 2023 06:41 pm ET
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival (PFS) of 5.5 months (median study follow-up time of 12.4 months)
May 31, 2023 07:45 am ET
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic hypersomnia
May 30, 2023 04:15 pm ET
Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference
DUBLIN, May 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 Goldman Sachs Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, June 13, 2023, at 3:20 p.m. PT / 11:20 p.m. IST.
May 25, 2023 04:15 pm ET
Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023
Zanidatamab data to be featured in oral presentation at ASCO 2023 Webcast to follow on June 2, 2023 at 6:45 p.m. CT
May 10, 2023 04:05 pm ET
Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance
Focus on commercial execution drove 1Q23 total revenues of $892.8 millionContinued adoption of Xywav®; net product sales increased 49% 1Q23 compared to 1Q22Confident in blockbuster potential of Epidiolex®; net product sales increased 20% 1Q23 compared to 1Q22Strong Rylaze® demand drove 58% increase in net product sales 1Q23 compared to 1Q22Enhanced pipeline positioned to deliver at least three late-stage data readouts by the end of 2024
May 02, 2023 04:15 pm ET
Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
DUBLIN, May 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 RBC Capital Markets Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, May 16, 2023, at 4:05 p.m. ET / 9:05 p.m. IST.
Apr 27, 2023 07:30 am ET
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate breakthrough HER2-targeted pan-tumor potential
Apr 26, 2023 04:15 pm ET
Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023
DUBLIN, April 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 first quarter financial results on Wednesday, May 10, 2023, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2023 first quarter financial results and provide a business and financial update.  
Apr 19, 2023 07:45 am ET
Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting
Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders
Mar 30, 2023 07:44 am ET
Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health
Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy organizations
Mar 15, 2023 07:00 am ET
Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline
DUBLIN, March 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023. Research findings to be presented include data from company-sponsored and collaborative trials studying Zepzelca® (lurbinectedin), zanidatamab and JZP898.
Mar 08, 2023 07:00 am ET
Jazz Pharmaceuticals Secures Eight Additional Provincial Reimbursements for Vyxeos® for Treatment of Adults with Newly Diagnosed Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with M
MISSISSAUGA, ON, March 8, 2023 /CNW/ - Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced today that Vyxeos® (daunorubicin and cytarabine liposome for injection) is now included on eight additional provincial drug formularies, including British Columbia, Ontario, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Alberta, and Newfoundland and Labrador. Vyxeos is indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC).1
Feb 27, 2023 03:15 pm ET
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
DUBLIN, Feb. 27, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor conferences:
Jan 19, 2023 06:45 am ET
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 12.5 months
Jan 03, 2023 06:30 am ET
Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
DUBLIN, Jan. 3, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 9, 2023, at 3:45 p.m. PST / 11:45 p.m. GMT.
Dec 21, 2022 06:30 am ET
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers
Dec 05, 2022 07:00 am ET
Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies
Real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) Caregiver Survey presented at the 2022 American Epilepsy Society Annual Meeting expands evidence behind Epidiolex treatment in adult and pediatric patients
Nov 28, 2022 07:09 am ET
Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting
Data from six abstracts to be presented, including new long-term Phase 3 results and two real-world analyses of U.S. caregiver-reported seizure and non-seizure outcomes in patients prescribed Epidiolex ®(cannabidiol)
Nov 18, 2022 12:00 pm ET
Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)
Rylaze dosing options provide sustained asparaginase activity throughout the entire course of treatment for adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma
Nov 14, 2022 08:00 am ET
STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING
LOS ANGELES, Nov. 14, 2022 /PRNewswire/ -- Stand Up To Cancer® (SU2C) announced today the launch of a new public service announcement (PSA) campaign in partnership with Jazz Pharmaceuticals plc. The PSA aims to raise awareness in Black and Hispanic communities about small cell lung cancer and encourage listeners to learn about screening options. The radio PSA campaign launches nationally today in both English and Spanish.
Nov 09, 2022 03:05 pm ET
Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
DUBLIN, Nov. 9, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2022, and raised the mid-point of 2022 total revenue guidance.
Nov 03, 2022 10:42 am ET
Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research
Key data includes results for intravenous administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients
Nov 01, 2022 04:15 pm ET
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
DUBLIN, Nov. 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming investor conferences:
Oct 26, 2022 04:15 pm ET
Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022
DUBLIN, Oct. 26, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 third quarter financial results on Wednesday, November 9, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2022 third quarter financial results and provide a business and financial update.
Oct 19, 2022 06:00 am ET
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan 
Oct 19, 2022 06:00 am ET
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan 
Sep 29, 2022 12:59 pm ET
Thinking about trading options or stock in Wix.Com, Jazz Pharmaceuticals, Visa, Chevron, or Tesla?
NEW YORK, Sept. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WIX, JAZZ, V, CVX, and TSLA.
Sep 15, 2022 04:30 pm ET
Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022
Seven abstracts emphasize Jazz's leadership in neuroscience and commitment to ongoing innovation
Aug 31, 2022 04:15 pm ET
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
DUBLIN, Aug. 31, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming investor conferences:
Aug 18, 2022 07:30 am ET
Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures
Trial is the first randomized, controlled clinical trial evaluating cannabidiol to treat children and adolescents living with a developmental and epileptic encephalopathy known as Epilepsy with Myoclonic-Atonic Seizures
Aug 03, 2022 04:05 pm ET
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
DUBLIN, Aug. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance1 and provided business updates.
Jul 20, 2022 04:15 pm ET
Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
DUBLIN, July 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 second quarter financial results on Wednesday, August 3, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2022 second quarter financial results and provide a business and financial update.  
Jun 28, 2022 07:30 am ET
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple sclerosis spasticity
Jun 07, 2022 07:30 am ET
Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO
Oral presentation confirms patients achieved clinically meaningful nadir serum asparaginase activity throughout the course of Rylaze treatment with intramuscular dosing regimen administered 25/25/50 mg/m2 on Monday/Wednesday/Friday
Jun 01, 2022 04:15 pm ET
Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference
DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST in New York.  
Jun 01, 2022 07:45 am ET
Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine
Seventeen abstracts debut new data across narcolepsy and idiopathic hypersomnia
May 12, 2022 11:57 am ET
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings
Key data includes ASCO oral presentation of data from the Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
May 09, 2022 07:00 am ET
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics
DUBLIN, May 9, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has completed the divestiture of Sunosi® (solriamfetol) in the U.S. to Axsome Therapeutics, Inc. (Nasdaq: AXSM).
May 04, 2022 04:10 pm ET
Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance
DUBLIN, May 4, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2022, raised 2022 financial guidance and provided business updates.
May 04, 2022 04:05 pm ET
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
Jazz licenses development and commercialization rights in U.S., Europe and other territories; Sumitomo Pharma retains rights in Japan, China and other Asia/Pacific territories
May 03, 2022 04:15 pm ET
Jazz Pharmaceuticals to Participate in the BofA Securities 2022 Global Healthcare Conference
DUBLIN, May 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2022 Global Healthcare Conference on Tuesday, May 10, 2022, at 12:40 p.m. PT / 3:40 p.m. ET / 8:40 p.m. IST in Las Vegas.  
Apr 20, 2022 04:15 pm ET
Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022
DUBLIN, April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 first quarter financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2022 first quarter financial results and provide a business and financial update.  
Apr 08, 2022 01:00 pm ET
Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types
Novel, investigational drug JZP815 inhibited tumor growth in several RAS- and BRAF-mutated solid tumor models, and demonstrated enhanced activity when combined with other MAPK pathway inhibitors
Apr 07, 2022 07:00 am ET
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule
Werewolf to receive $15 million upfront payment, with potential for up to $1.26 billion in development, regulatory and sales milestone payments in addition to royalties on future net sales
Mar 29, 2022 04:15 pm ET
Jazz Pharmaceuticals to Participate in Upcoming April Investor Conferences
DUBLIN, March 29, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor conferences:
Mar 28, 2022 06:00 am ET
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics
Jazz to receive $53 million upfront cash payment, and royalty rights
Mar 25, 2022 03:00 am ET
Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing
Construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved cannabis-based medicines
Mar 24, 2022 07:30 am ET
Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors
Open-label basket trial will assess the safety and efficacy of Zepzelca in patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination deficient tumors
Mar 08, 2022 03:35 pm ET
Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting
DUBLIN, March 8, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that pre-clinical data on JZP815, an investigational, next-generation pan-RAF kinase inhibitor, will be presented as a poster at the American Association for Cancer Research (AACR) 2022 Annual Meeting from April 8-13, 2022.
Mar 01, 2022 03:05 pm ET
JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS
DUBLIN, March 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provided financial guidance for 2022.
Feb 28, 2022 03:15 pm ET
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming virtual investor conferences:
Feb 15, 2022 03:15 pm ET
Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022
DUBLIN, Feb. 15, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 fourth quarter and full year financial results on Tuesday, March 1, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2021 fourth quarter and full year financial results and provide a business and financial update.  
Feb 02, 2022 06:30 am ET
Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule
DUBLIN, Feb. 2, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company has completed the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval for a Monday/Wednesday/Friday (M/W/F) intramuscular (IM) dosing schedule for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients one month and
Jan 10, 2022 08:31 am ET
Thinking about trading options or stock in Jazz Pharmaceuticals, ViacomCBS, Progressive, Tesla, or Exxon Mobil?
NEW YORK, Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAZZ, VIAC, PGR, TSLA, and XOM.
Jan 10, 2022 06:30 am ET
Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader
DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its Vision 2025 to deliver sustainable growth and enhanced value. Vision 2025 includes the following expectations: 1) generating $5 billion in revenue in 2025; 2) approval of at least five additional novel products by the end of the decade; and 3) realizing a 5% adjusted operating margin1 improvement from 2021 to 2025, driven by operational excellence. The Company also confirmed that it expects to meet its previously announced 2021 revenue guidance range of $3.02 to $3.1 billion and its net product
Jan 05, 2022 06:45 am ET
Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia
DUBLIN, Jan. 5, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive data from the Phase 3 multicenter, placebo-controlled, double-blind, randomized withdrawal study of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of adults with idiopathic hypersomnia were published online in The Lancet Neurology.
Jan 03, 2022 03:15 pm ET
Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
DUBLIN, Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced Bruce Cozadd, chairman and chief executive officer, will present virtually as part of the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, from 2:15 – 2:55 p.m. ET / 7:15 – 7:55 p.m. GMT.  
Jan 03, 2022 03:10 pm ET
U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
DUBLIN, Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of idiopathic hypersomnia in adults, making it the second ODE for the medication following the exclusivity granted in the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Dec 30, 2021 06:45 am ET
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder
DUBLIN, Dec. 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). JZP150 is a highly selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), designed to address the underlying cause of PTSD (impairment of fear extinction and its consolidation), as well as patients' associated symptoms (anxiety, insomnia and nightmares).
Dec 15, 2021 06:45 am ET
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor
DUBLIN, Dec. 15, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the safety and efficacy of suvecaltamide (also known as JZP385), a highly selective modulator of T-type calcium channels in development for the potential treatment of moderate to severe essential tremor (ET).1 The multicenter, double-blind, randomized, placebo-controlled trial will evaluate adults with moderate to severe ET treated with a once-daily oral capsule of suvecaltamide or placebo. ET is the most common
Dec 13, 2021 01:30 am ET
PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
MADRID and DUBLIN, Dec. 13, 2021 /PRNewswire/ -- PharmaMar (MSE: PHM) and partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the initiation of a confirmatory Phase 3 clinical trial, LAGOON, evaluating Zepzelca® (lurbinectedin) for the treatment of patients with relapsed small cell lung cancer (SCLC). The trial will measure overall survival (OS) as the primary endpoint and progression-free survival (PFS) as a secondary endpoint of lurbinectedin monotherapy or lurbinectedin in combination with irinotecan compared with investigator's choice of topotecan or irinotecan, in patients w
Dec 12, 2021 08:00 am ET
Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021
DUBLIN, Dec. 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity or silent inactivation to an E. coli-derived asparaginase. The study was developed and conducted in close collaboration with the Children's Oncology Group (COG). These initial results will be presented for the fi
Dec 01, 2021 06:45 am ET
Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting
DUBLIN, Dec. 1, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations, including one late-breaking abstract, will be debuted at the upcoming 2021 American Epilepsy Society (AES) annual meeting, which will be held December 3 to 7, 2021 in Chicago, IL.
Nov 30, 2021 07:00 am ET
Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer
DUBLIN, Nov. 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient was enrolled in a Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor Tecentriq® (atezolizumab) as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The trial, IMforte, conducted in collaboration with F. Hoffmann-La Roche Ltd, will measure the progression-free survival and overall survival benefits of Zepzelca and Tecentriq administered in combination compared to Tecentriq alon
Nov 30, 2021 06:45 am ET
Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca™ (lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a Decade
DUBLIN, Nov. 30, 2021 /CNW/ - Jazz Pharmaceuticals plc (NASDAQ: JAZZ) along with partner PharmaMar (MSE: PHM) have announced the commercial availability of ZepzelcaTM (lurbinectedin) after receiving conditional approval by Health Canada in September 2021. Zepzelca is the first new treatment in Canada for adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy in more than a decade.1 
Nov 09, 2021 03:15 pm ET
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
DUBLIN, Nov. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will virtually participate in the following upcoming investor conferences:
Nov 09, 2021 03:05 pm ET
Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance
DUBLIN, Nov. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2021 and updated financial guidance for 2021.
Nov 04, 2021 11:04 am ET
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting
DUBLIN, Nov. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, which will be held December 11-14, 2021. This includes five presentations from investigator-sponsored trials and three presentations from collaboration studies with The University of Texas MD Anderson Cancer Center (MD Anderson).
Oct 26, 2021 04:15 pm ET
Jazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021
DUBLIN, Oct. 26, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 third quarter financial results on Tuesday, November 9, 2021 after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET/9:30 p.m. IST to discuss 2021 third quarter financial results and provide a business and financial update. 
Sep 13, 2021 04:15 pm ET
Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021
DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on Xywav® (calcium, magnesium, potassium and sodium oxybates), the first and only U.S. Food and Drug Administration-approved treatment for idiopathic hypersomnia (IH) in adults, which was approved on August 12, 2021.
Sep 08, 2021 04:15 pm ET
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
DUBLIN, Sept. 8, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences:
Aug 31, 2021 08:00 am ET
Jazz Pharmaceuticals Announces Health Canada Approval of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, Aug. 31, 2021 /CNW/ - Jazz Pharmaceuticals plc (NASDAQ: JAZZ) today announced the Health Canada approval and availability of Sunosi® (solriamfetol) for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) in adult patients. Once-daily Sunosi is approved with doses of 75 mg and 150 mg.1 
Aug 12, 2021 02:30 pm ET
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
DUBLIN, Aug. 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults.1 The company plans to make Xywav available to patients with idiopathic hypersomnia later this year following Risk Evaluation and Mitigation Strategies (REMS) implementation.
Aug 10, 2021 08:00 am ET
Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers
LOS ANGELES, Aug. 10, 2021 /PRNewswire/ -- Stand Up To Cancer® (SU2C) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announce a three-year, $4 million research collaboration to explore new opportunities, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers. The collaboration also includes digital ethnography research to identify barriers to treatment and to gain insights and perspectives about small cell lung cancer (SCLC) from patients and caregivers in underserved communities.
Aug 10, 2021 04:24 am ET
GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex
LONDON, Aug. 10, 2021 /PRNewswire/ -- GW Pharmaceuticals ("GW"), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines and now part of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), today announces that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new indication for GW's cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older.
Aug 03, 2021 04:05 pm ET
Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results
DUBLIN, Aug. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2021 and affirmed non-GAAP adjusted financial guidance for 2021.
Jul 22, 2021 04:15 pm ET
National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia
DUBLIN, July 22, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN) added Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL), for both pediatric and adult patients.
Jul 20, 2021 04:15 pm ET
Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021
DUBLIN, July 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 second quarter financial results on Tuesday, August 3, 2021 after the close of the financial markets. Company management will host a live audio webcast at 4:30 p.m. ET/9:30 p.m. IST to discuss second quarter 2021 financial results and provide a business and financial update.  
Jul 13, 2021 04:15 pm ET
Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021
DUBLIN, July 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Tuesday, July 20, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), which was approved by the U.S. Food and Drug Administration (FDA) on June 30, 2021.
Jul 07, 2021 07:45 am ET
Health Canada Approves Vyxeos®, the First Chemotherapy Advance in over 40 years for Adults with High-risk Acute Myeloid Leukemia (AML)
DUBLIN, July 7, 2021 /CNW/ - Jazz Pharmaceuticals plc (NASDAQ: JAZZ) today announced the Health Canada approval and availability of Vyxeos® (daunorubicin and cytarabine liposome for injection) for the treatment of adults with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).1
Jul 06, 2021 06:17 pm ET
Horizons ETFs Rebalances Marijuana-Focused Index Etfs
TORONTO, July 6, 2021 /CNW/ - Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") has completed the quarterly rebalances of the holdings of the Horizons Marijuana Life Sciences Index ETF ("HMMJ":TSX) and the Horizons US Marijuana Index ETF ("HMUS":NEO).
Jun 30, 2021 08:04 pm ET
Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase.1 Rylaze is the only recombinant erwinia asparaginase manufactured product that maintains a clinically meaningfu
Jun 25, 2021 07:45 am ET
Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
U.S. Food and Drug Administration published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy by means of greater safety compared to Xyrem® (sodium oxybate)
Jun 17, 2021 07:30 am ET
Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc
DUBLIN, June 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today updated its full year 2021 financial guidance to incorporate the GW Pharmaceuticals (GW) business, which the Company acquired on May 5, 2021.
Jun 14, 2021 07:30 am ET
Jazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch First and Only Digital Hub Focused Exclusively on Emotional, Social and Physical Health Needs of Small Cell Lung Cancer Comm
DUBLIN, June 14, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Nothing Small About It (www.nothingsmallaboutit.com), an online program developed with consultation from leading cancer organizations CancerCare, GO2 Foundation for Lung Cancer, Lung Cancer Foundation of America and LUNGevity Foundation. Nothing Small About It is the first digital hub for U.S. audiences dedicated solely to small cell lung cancer (SCLC) patients and caregivers, and it provides user-friendly content that puts real people and their stories at the center of the experience,
Jun 09, 2021 07:45 am ET
Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021
DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021, the 35th annual meeting of the Associated Professional Sleep Societies (APSS) from June 10-13, 2021.
Apr 23, 2021 04:01 pm ET
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals
GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW’s shareholders voted to approve the acquisition of GW by a subsidiary of Jazz (or its nominee(s)) at the GW shareholder meetings...
Apr 05, 2021 06:00 am ET
Oyster Point Pharma Announces New Appointment to Board of Directors
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the...
Feb 23, 2021 03:10 pm ET
Jazz Pharmaceuticals Announces Participation at Cowen 41st Annual Healthcare Conference
DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Cowen 41st Annual Healthcare conference.
Feb 23, 2021 03:05 pm ET
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results
DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021.
Feb 17, 2021 03:05 pm ET
Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference
DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Leerink 10th Annual Global Healthcare Conference.
Feb 16, 2021 07:00 am ET
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress
GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the fourth quarter and full-year ended...
Feb 16, 2021 06:45 am ET
Jazz Pharmaceuticals Completes Submission of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia
DUBLIN, Feb. 16, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of adult patients with idiopathic hypersomnia. If approved, Xywav will be the first and only approved treatment in the U.S. for adults with idiopathic hypersomnia. 
Feb 09, 2021 03:05 pm ET
Jazz Pharmaceuticals to Report 2020 Fourth Quarter Financial Results on February 23, 2021
DUBLIN, Feb. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 fourth quarter and full year financial results on Tuesday, February 23, 2021, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss fourth quarter 2020 financial results and provide a business and financial update.  
Feb 05, 2021 10:00 am ET
Should you invest in Nio, Snap, Bank of America, Electronic Arts, or Jazz Pharmaceuticals?
NEW YORK, Feb. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, SNAP, BAC, EA, and JAZZ.
Feb 03, 2021 05:32 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of GW Pharmaceuticals plc Buyout
Rigrodsky Law, P.A. announces that it is investigating GW Pharmaceuticals plc (“GW Pharmaceuticals”) (NASDAQ GM: GWPH) regarding possible breaches of fiduciary duties and other violations of law related to GW Pharmaceuticals’ agreement to be...
Feb 03, 2021 03:46 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates GW Pharmaceuticals plc
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GW Pharmaceuticals plc ("GWPH" or the "Company") (NASDAQ: GWPH) in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals Public Limited Company ("Jazz") (NASDAQ: JAZZ).  Under the terms of the merger agreement, Jazz will acquire GWPH in a mixed cash-and-stock transaction for $220.00 per American Depositary Share ("ADS"), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares.  The proposed transa
Feb 03, 2021 12:14 pm ET
GW PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of GWPH and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of GW Pharmaceuticals plc (NASDAQ: GWPH) breached their fiduciary duties or violated the federal...
Feb 03, 2021 10:00 am ET
Should you invest in Vaxart, Inovio Pharmaceuticals, Virgin Galactic, Blink Charging, or Jazz Pharmaceuticals?
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VXRT, INO, SPCE, BLNK, and JAZZ.
Feb 03, 2021 06:30 am ET
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader
DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021.
Jan 04, 2021 03:05 pm ET
Jazz Pharmaceuticals Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference
DUBLIN, Jan. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference.
Dec 21, 2020 07:00 am ET
Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, Dec. 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has initiated the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for JZP-458 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. 
Dec 03, 2020 01:00 am ET
Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum
DUBLIN, Dec. 3, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, randomized, controlled study evaluating Zepzelca™ (lurbinectedin) in combination with doxorubicin versus physician's choice of topotecan or cyclophosphamide/doxorubicin/vincristine (CAV) for adult patients with small cell lung cancer (SCLC) whose disease progressed following one prior platinum-containing line. Patients received lurbinectedin at 2.0mg/m2 in the combination arm, which is lower than the FDA appr
Nov 17, 2020 06:30 am ET
Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors
DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jennifer Cook and Mark D. Smith, M.D. have been appointed to the Company's Board of Directors, effective December 1, 2020.
Nov 10, 2020 03:05 pm ET
Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference
DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the following virtual healthcare conference:
Nov 05, 2020 06:30 am ET
Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology/Oncology Research
DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 11 company-sponsored abstracts, in addition to two abstracts from collaboration trials with The University of Texas MD Anderson Cancer Center (MD Anderson), one abstract from a cooperative group trial and four abstracts from investigator-sponsored trials, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting, which will be held December 5-8, 2020 as a virtual event.
Nov 02, 2020 03:05 pm ET
Jazz Pharmaceuticals Announces Third Quarter 2020 Financial Results
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2020 and updated its 2020 financial guidance.
Oct 26, 2020 07:30 am ET
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) ("SpringWorks") today announced that Jazz Pharmaceuticals Ireland Limited ("Jazz") and SpringWorks have entered into an asset purchase and exclusive license agreement under which Jazz has acquired SpringWorks' fatty acid amide hydrolase ("FAAH") inhibitor program including PF-04457845. Jazz will initially focus on developing PF-04457845 for the potential treatment of post-traumatic stress disorder ("PTSD") and associated symptoms. 
Oct 20, 2020 07:30 am ET
Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients wit
DUBLIN, Oct. 20, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the publication of the global Phase 3 double-blind, placebo-controlled, randomized-withdrawal, multicenter study of Xywav™ (calcium, magnesium, potassium and sodium oxybates) oral solution, for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. The results were published in SLEEP, the peer-reviewed, international journal of the Sleep Research Society.
Oct 19, 2020 04:15 pm ET
Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update
DUBLIN, Oct. 19, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, October 26, 2020 at 4:30 p.m. EDT / 8:30 p.m. GMT to provide investors with an update on Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, which was approved by the U.S. Food and Drug Administration on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.  The company expects Xywav to be commercially available in early November.
Oct 19, 2020 04:05 pm ET
Jazz Pharmaceuticals to Report 2020 Third Quarter Financial Results on November 2, 2020
DUBLIN, Oct. 19, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 third quarter financial results on Monday, November 2, 2020, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss third quarter 2020 financial results and provide a business and financial update.  
Oct 14, 2020 04:05 pm ET
New Data for Zepzelca™ (lurbinectedin) to be Presented at IASLC 2020 North America Conference on Lung Cancer
DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its partner PharmaMar (MSE: PHM) today announced they will present new data for Zepzelca™ (lurbinectedin) in small cell lung cancer (SCLC) at the International Association for the Study of Lung Cancer (IASLC) 2020 North America Conference on Lung Cancer, which will be held October 16-17, 2020 as a virtual event.
Aug 04, 2020 04:05 pm ET
Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results
DUBLIN, Aug. 4, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance.
Jul 22, 2020 07:30 am ET
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
DUBLIN, July 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.1,2 Xywav is an oxybate product with a unique composition of cations resulting in 92 percent less sodium – or approximately 1,000 to 1,500 mg/night – than sodium oxybate at the recommended dosage range of 6 to 9 grams.1
Jul 21, 2020 04:05 pm ET
Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020
DUBLIN, July 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 second quarter financial results on Tuesday, August 4, 2020, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss second quarter 2020 financial results and provide a business and financial update.  
Jul 13, 2020 08:00 am ET
National Comprehensive Cancer Network® adds Zepzelca™ (lurbinectedin) to Clinical Practice Guidelines in Oncology
DUBLIN, July 13, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Zepzelca™ (lurbinectedin) was added by the National Comprehensive Cancer Network (NCCN®) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for small cell lung cancer (SCLC) on July 7, 2020.
Jun 15, 2020 03:35 pm ET
Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
DUBLIN, June 15, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced along with its partner PharmaMar (MSE: PHM) that the U.S. Food and Drug Administration (FDA) approved Zepzelca™ (lurbinectedin) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.1 Zepzelca was approved under accelerated approval based on overall response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a
Jun 09, 2020 07:00 am ET
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026
DUBLIN, June 9, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 2.000% exchangeable senior notes due 2026 in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").  The Issuer also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $150 million aggregate principal
Jun 08, 2020 07:00 am ET
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026
DUBLIN, June 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $850 million aggregate principal amount of exchangeable senior notes due 2026 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").  The Issuer also expects to grant the initial purchasers of the notes a 13-day option to purchase up to an
May 27, 2020 04:05 pm ET
Jazz Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
DUBLIN, May 27, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences:
May 14, 2020 09:53 am ET
Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings
DUBLIN, May 14, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its partners will present seven new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from May 29-June 2, 2020 and six abstracts at the virtual 25th Annual Congress of the European Hematology Association (EHA) from June 11-14, 2020. These new data from Jazz's expanding hematology and oncology portfolio and pipeline are focused on difficult-to-treat cancers, or related disorders, which have few, if any, treatment options.  
May 11, 2020 08:30 am ET
Bionical Emas and Jazz Pharmaceuticals Enter into an Agreement for Expanded Access to Lurbinectedin in Relapsed Small Cell Lung Cancer in the United States
WILLINGTON, England and DUBLIN, May 11, 2020 /PRNewswire/ -- Bionical Emas and Jazz Pharmaceuticals (NASDAQ: JAZZ) have entered into an agreement to provide appropriate patients in the United States (U.S.) who have relapsed Small Cell Lung Cancer (SCLC) lurbinectedin via an Expanded Access Program (EAP). Lurbinectedin is an investigational drug under review by the U.S. Food and Drug Administration (FDA).
May 11, 2020 08:30 am ET
Jazz Pharmaceuticals Announces Appointment Of Kim Sablich As Executive Vice President, General Manager Of North America
DUBLIN, May 11, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Kim Sablich as executive vice president, general manager of North America, effective June 1, 2020. In this role, Ms. Sablich will lead Jazz's newly formed North American regional business structure, including Canada and the U.S., which brings together Medical Affairs, Commercial and Market Access teams for North America to create a strategically-aligned and integrated customer-facing organization. Ms. Sablich will report to Daniel Swisher, president and chief operating officer. 
May 06, 2020 04:05 pm ET
Jazz Pharmaceuticals Announces Participation at Upcoming Virtual Investor Conferences
DUBLIN, May 6, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences:
May 05, 2020 04:05 pm ET
Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results
DUBLIN, May 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2020 and updated 2020 financial guidance.
Apr 29, 2020 04:05 pm ET
Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease
DUBLIN, April 29, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-cell transplantation (HSCT) in high-risk or very high-risk patients is being discontinued. Enrollment in the study was stopped early based on the recommendation from an Independent Data Monitoring Committee (IDMC), which concluded it would be highly unlikely to reach statistical significance for the primary endpoint of VOD-free survival at Day +30 post-HSCT
Apr 21, 2020 04:05 pm ET
Jazz Pharmaceuticals to Report 2020 First Quarter Financial Results on May 5, 2020
DUBLIN, April 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 first quarter financial results on Tuesday, May 5, 2020, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss first quarter 2020 financial results and provide a business and financial update.  
Mar 31, 2020 04:01 pm ET
Jazz Pharmaceuticals Provides COVID-19 Business Update
DUBLIN, March 31, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today provided an update regarding the impact of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus.
Mar 25, 2020 04:05 pm ET
Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
DUBLIN, March 25, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the company's New Drug Application (NDA) seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92%, or approximately 1,000 to 1,500 milligrams, less sodium than Xyrem® (sodium oxyba
Nov 15, 2019 05:45 am ET
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, Nov. 15, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorisation of solriamfetol to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).1
Nov 14, 2019 03:05 pm ET
Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
DUBLIN, Nov. 14, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at three upcoming investor conferences.
Nov 07, 2019 07:00 am ET
Jazz Pharmaceuticals to Highlight Growing Hematology Oncology Pipeline at ASH 2019 Annual Meeting
DUBLIN, Nov. 7, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 15 abstracts sponsored by Jazz Pharmaceuticals, including one oral presentation, one abstract from a collaboration trial with MD Anderson Cancer Center (MD Anderson) and two abstracts from investigator-sponsored trials, will be presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando from December 7-10, 2019.
Nov 05, 2019 03:05 pm ET
Jazz Pharmaceuticals Announces Third Quarter 2019 Financial Results
DUBLIN, Nov. 5, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2019 and updated 2019 financial guidance.
Oct 22, 2019 04:05 pm ET
Jazz Pharmaceuticals to Report 2019 Third Quarter Financial Results on November 5, 2019
DUBLIN, Oct. 22, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 third quarter financial results on Tuesday, November 5, 2019, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss third quarter 2019 financial results and provide a business and financial update.
Oct 10, 2019 04:15 pm ET
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity
DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in an exploratory Phase 2 clinical trial evaluating the ability of defibrotide to prevent neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) receiving CAR T-cell therapy. The prospective, multicenter, open-label, single-arm study will evaluate the safety and efficacy of defibrotide in the prevention of CAR T-cell associated neurotoxicity in patients with relapsed or refractory DLBCL receiving axicabtagene ciloleucel.
Sep 30, 2019 08:30 am ET
Jazz Pharmaceuticals Survey Highlights Prevalence of Misinformation and Misperception About Narcolepsy Among Americans
DUBLIN, Sept. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the results of a consumer survey of more than 1,000 Americans measuring public perception and knowledge of sleep disorders like narcolepsy. Narcolepsy is a serious condition that is often overlooked and misunderstood, and people with narcolepsy can live with symptoms for years before receiving a proper diagnosis.1 It is estimated that half of people living with narcolepsy may not know they have the chronic neurological condition.2
Sep 25, 2019 08:00 pm ET
Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019
DUBLIN, Sept. 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that positive data from the Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adults with narcolepsy were presented at World Sleep 2019 in Vancouver, Canada. Data from the study were presented in an oral presentation today at 5:00 p.m. PDT and in a poster presentation on September 24.
Aug 27, 2019 04:05 pm ET
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
DUBLIN, Aug. 27, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.
Aug 12, 2019 04:01 pm ET
Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.
DUBLIN, Aug. 12, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the acquisition of Cavion, Inc. through a merger with a Jazz subsidiary.  Under the terms of the agreement, the former Cavion shareholders receive an upfront payment of $52.5 million and have the potential to receive additional payments of up to $260.0 million upon the achievement of certain clinical, regulatory and commercial milestones, for a total potential consideration of $312.5 million. 
Aug 06, 2019 04:05 pm ET
Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results
DUBLIN, Aug. 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2019 and updated 2019 financial guidance.
Aug 06, 2019 04:01 pm ET
Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program
DUBLIN, Aug. 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Phase 1 study of its recombinant crisantaspase molecule, JZP-458, met its efficacy and safety objectives. The company plans to initiate a single-arm, pivotal Phase 2/3 study evaluating JZP-458 as a potential treatment option for patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginase products.
Jul 23, 2019 04:05 pm ET
Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019
DUBLIN, July 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 second quarter financial results on Tuesday, August 6, 2019, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss second quarter 2019 financial results and provide a business and financial update.
Jul 10, 2019 02:00 am ET
Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma
DUBLIN, July 10, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a definitive agreement under which Jazz has acquired Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors.  Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz.  Jazz will be responsible for further development, regulatory activities and commercialization.
May 16, 2019 04:30 pm ET
Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress
DUBLIN, May 16, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that it will present data from across its hematology/oncology portfolio and pipeline at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31-June 4, 2019 and at the 24th Congress of the European Hematology Association (EHA) in Amsterdam from June 13-16, 2019.
May 09, 2019 08:00 am ET
Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019
DUBLIN, May 9, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that 14 abstracts sponsored by Jazz Pharmaceuticals and one abstract from an investigator-sponsored trial will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies, known as "SLEEP," in San Antonio from June 8-12, 2019.
May 07, 2019 04:05 pm ET
Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results
DUBLIN, May 7, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2019 and reaffirmed 2019 financial guidance.
May 06, 2019 04:05 pm ET
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
DUBLIN, May 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.
Apr 23, 2019 04:05 pm ET
Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019
DUBLIN, April 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss first quarter 2019 financial results and provide a business and financial update.
Apr 16, 2019 07:50 am ET
Report: Developing Opportunities within Noble, Harris, Jazz Pharmaceuticals, Teradata, Abeona Therapeutics, and Otonomy — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Noble Corporation (NYSE:NE), Harris Corporation (NYSE:HRS), Jazz...
Mar 26, 2019 04:13 pm ET
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
DUBLIN, March 26, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the global, double-blind, placebo-controlled, randomized-withdrawal, multicenter Phase 3 study evaluating the efficacy and safety of JZP-258 for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult patients with narcolepsy. JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92% less sodium than Xyrem® (sodium oxybate).
Mar 20, 2019 06:53 pm ET
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, March 20, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). Once-daily Sunosi is approved with doses of 75 mg and 150 mg for patients with narcolepsy and doses of 37.5 mg, 75 mg, and 150 mg for patients with OSA. Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved to treat excessive daytime sleepiness
Mar 05, 2019 03:05 pm ET
Jazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
DUBLIN, March 5, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Cowen and Company 39th Annual Healthcare Conference in Boston, MA.
Feb 26, 2019 03:05 pm ET
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results
DUBLIN, Feb. 26, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2018 and provided financial guidance for 2019.
Feb 15, 2019 08:10 am ET
New Research: Key Drivers of Growth for IPG Photonics, Keane Group, Jazz Pharmaceuticals, Tredegar, Carriage Services, and Surgery Partners — Factors of Influence, Major Initiatives and Sustained Prod
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IPG Photonics Corporation (NASDAQ:IPGP), Keane Group, Inc. (NYSE:FRAC),...
Feb 14, 2019 03:05 pm ET
Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors
DUBLIN, Feb. 14, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Anne O'Riordan, Senior Managing Director, Life Sciences of Accenture, was appointed to its Board of Directors, effective February 14, 2019.  The appointment increases the size of the Jazz Board of Directors to 12 members. 
Feb 12, 2019 03:05 pm ET
Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019
DUBLIN, Feb. 12, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss fourth quarter and full year 2018 financial results and provide a business and financial update and guidance for 2019 financial results.
Jan 03, 2019 03:05 pm ET
Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers
DUBLIN and CAMBRIDGE, Mass., Jan. 3, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Codiak BioSciences, Inc. today announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of exosome therapeutics to treat cancer. Codiak granted Jazz an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize therapeutic candidates directed at five targets to be developed using Codiak's engEx™ precision engineering platform for exosome therapeutics. The targets focus on oncogen
Dec 21, 2018 06:00 am ET
Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, Dec. 21, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for solriamfetol as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). The updated Prescription Drug User Fee Act (PDUFA) goal date is now March 20, 2019.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.